ClinicalTrials.gg
RecruitingNCT07136415CELESTEUpdated Jun 8, 2026

Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms

A Phase 4 interventional study of Cognitive behavioral therapy for insomnia (CBT-i) and Trazodone in Menopausal Women and Insomnia, sponsored by Brigham and Women's Hospital. Recruiting at 5 sites in United States. Open to female participants aged 40 Years to 62 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Brigham and Women's Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
40 Years to 62 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing trazodone in Sleep Initiation and Maintenance Disorders — 4 open to participants now, 4 under way, none of them phase 3. Trazodone · Sleep Initiation and Maintenance Disorders.

Planned enrollment
2nd of 12
1,000 · median 146
Started
2026
with 1 other
Phase 4
4 of 12
2 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
Brigham and Women's Hospital

Among the 12 studies testing trazodone in Sleep Initiation and Maintenance Disorders, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2026, is one of 4 in phase 4, and was the 11th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

4 of the 12 studies testing trazodone in Sleep Initiation and Maintenance Disorders are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About trazodone

Trazodone: first FDA approval 1981 (DESYREL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 40 Years to 62 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing trazodone in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn how three current insomnia therapies (trazodone, daridorexant, cognitive behavioral therapy for insomnia) compare with each other in peri- and post-menopausal women. It will also learn about the safety of the treatments. The main questions it aims to answer are:

Which commonly used insomnia therapies are most effective and safe for improving insomnia symptoms in peri- and post-menopausal people?

How well do the treatments work for people from different backgrounds, who are at different stages of menopause, and who have different conditions common during menopause (e.g., sleep apnea, mood disturbance, etc.)?

What medical problems do participants have when using these treatments?

Participants will:

Be asked to take trazodone every night, take daridorexant every night, or participate in an online behavioral program for insomnia, for a total of 12 months.

Participate in a total of one in-person visit and 7 virtual visits (phone calls) over the 12 months.

Wear (and keep) a Fitbit and fill out a daily sleep diary for at least 4 weeks over the 12 months.

Fill out online surveys 4 times over the 12 months.

Read the detailed description

Insomnia, or trouble sleeping, is common. It affects about 1 in 10 adults. People with insomnia are not happy with how long or how well they sleep. Insomnia has been linked to a higher risk of depression, heart disease, memory problems, and lower quality of life. It can also lead to missing work and having accidents. Sleep problems like insomnia are also common or people going through perimenopause and post-menopause.

CBT-I teaches people to change behaviors and thoughts that make it hard to sleep. Daridorexant is an FDA-approved medicine for insomnia. Trazodone is FDA-approved to treat depression, but many doctors also prescribe it to help with sleep. This is called off-label use, which means it is used for a purpose the FDA has not officially approved. Studies show that trazodone is one of the most common medicines prescribed for insomnia in the United States.

We do not yet know how well CBT-I, trazodone, and daridorexant compare, especially for people in perimenopause and post-menopause. Throughout the duration of the study, the participant will be given one of the three therapies.

This study takes about 12 months to complete for each participant.

The following visits and procedures will happen:

Consent telephone or virtual call

Screening Visit: Baseline surveys, urine pregnancy test, electrocardiogram, height and weight assessment. The 7 days after this visit, the participant will also be asked to wear their Fitbit for 24 hours every day, fill out diaries in the morning and night, and wear a home sleep apnea test for one night.

Randomization Call: The participant will be randomized (like a flip of a coin) to receive one of the three insomnia therapies (CBT-I, trazodone, or daridorexant) a week after their baseline visit.

1-week and 4-weeks Call: Quick phone call with study staff for any study treatment adjustments.

3-Months and 6-Months Call/Visit: Fill out surveys. At 6-months, weight will be measured. During the visit window, the participant will also be asked to wear their Fitbit for 24 hours every day and fill in a sleep diary in the morning and night for a total of 7 days.

9-Months Call: Quick phone call with study staff to see if there are any issues.

12-Months Call/Visit: Fill out surveys. During the visit window, the participant will also be asked to wear their Fitbit for 24 hours every day and fill in a sleep diary in the morning and night for a total of 7 days. The Fitbit is for the participant to keep and does not have to be returned.

03

Conditions studied

  • Menopausal Women
  • Insomnia

Keywords

  • menopause
  • insomnia
  • cognitive behavioral therapy
  • trazodone
  • daridorexant
04

Who can participate

Ages eligible
40 Years to 62 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40-62 years
  • Assigned female sex at birth
  • In peri- or early menopause, following the STRAW criteria of self-report of irregular menstrual cycle or within 5 years from the last menstrual period. When menstrual markers are absent or unreliable (e.g., hysterectomy; endometrial ablation), participants must be older than 45 years old and report hot flashes
  • Insomnia severity index score > 10 at screening
  • Insomnia started or worsened during peri- or early menopause
  • English or Spanish speaking (Spanish-only speaking individuals will be recruited after full development of Spanish-facing materials, which may lag initial study start)

Exclusion criteria

Exclusion Criteria:

  • Untreated, previously diagnosed severe sleep apnea (self-report; chart review; clinician assessment)
  • Untreated, previously diagnosed moderate-severe restless legs syndrome (self-report; chart review)
  • Severe daytime sleepiness (Epworth Sleepiness Scale > 15) at screening
  • Sleep schedule issues that would impact effectiveness of the interventions (e.g., night shift workers with >1 night shift/week; main sleep period outside of 8pm - 11am)
  • Regular use of hypnotics > 2 nights/week
  • Limited internet access
  • Pregnant or lactating or positive urine pregnancy test at baseline visit
  • Prolonged (>460 ms) (by study baseline (EKG) or EKG report in medical record)
  • History of the following health conditions: Uncontrolled hypertension; heart disease such as arrhythmias requiring medication, cardiomyopathies, heart failure, clinically significant valvular heart disease, or severe coronary artery disease (unstable angina, myocardial infarction in the prior 6 months); hypersomnia or narcolepsy; bipolar disorder, severe depression, or psychosis ; seizure within the past year; use of opioids or substance use disorder; known allergy or to trazodone or daridorexant (self-report and chart review); known severe chronic liver disease (e.g. cirrhosis); end-stage renal disease on hemodialysis; other severe medical comorbidity (e.g. likely hospitalization within next 6 months or medical conditions that increase risk of participation at a study clinician's discretion)
  • Use of medications such as those that: Have known potential for significantly prolonging the QT interval (i.e. antiarrhythmics such as amiodarone, sotalol, quinidine, procainamide, dofetilide, and ibutilide), are strong inhibitors, or are moderate or strong CYP3A4 inducers
  • Use of one of the interventions in the past 6 months
  • Other conditions determined by the PI or study clinician to preclude study participation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,000 participants (estimated)

Study arms

  • Active comparator
    Cognitive behavioral therapy for insomnia (CBT-i)

    Participants will be asked to take part in the CBT-i program over the course of 6-9 weeks, with the option of revisiting content throughout the study duration (12 months).

    Behavioral: Cognitive behavioral therapy for insomnia (CBT-i)

  • Active comparator
    Trazodone

    Participants will be asked to take trazodone (oral pill administration) for the duration of the study (12 months), with safety monitoring conducted by study staff throughout the study. Dosage adjustments may occur.

    Drug: Trazodone

  • Active comparator
    Daridorexant

    Participants will be asked to take daridorexant (oral pill administration) for the duration of the study (12 months), with safety monitoring conducted by study staff throughout the study.

    Drug: Daridorexant

Interventions

  • BehavioralCognitive behavioral therapy for insomnia (CBT-i)

    This is a program called SHUT-i and is composed of six self-guided sessions on a website over 6-9 weeks. Each session will be about 45-60 minutes long. CBT-I involves changing behaviors that cause sleep problems to persist. However, it also includes teaching skills to teach the participant to identify thoughts and feelings that may contribute to sleep problems.

  • Trazodone is a heterocyclic medication that is FDA-approved for depression (starting dose 150mg). An estimated 4 in 5 trazodone prescriptions are for insomnia. Low-dose trazodone's frequent off-label use stems from a long-standing perception that trazodone is an effective and safer sleep aid compared to other drugs despite potential risks documented in small studies. A starting dosage of 25 mg will be used. After 1 week, patients will be instructed to increase the dose as needed to 50mg if tolerated. A second dose adjustment will be made at 4 weeks. At four weeks, study staff will contact participants and review medication adherence, and a standardized checklist will be used to assess ongoing symptoms and side effects and to consider an increase in dose to 100mg.

  • Daridorexant is a DORA drug. Dual orexin receptor antagonists (DORAs) are the newest class of FDA-approved medications for insomnia based on efficacy data from pivotal clinical trials demonstrating their efficacy for sleep onset and maintenance. A single dose of 50 mg (1 pill each night within 30 minutes of bedtime) was selected based on better efficacy without evidence of higher risks than the 25mg dose. However, 25mg dosage will be instructed if the participant has moderate liver impairment and/or taking a moderate CYP3A4 inhibitor.

06

What researchers measure

Primary outcomes

  1. PROMIS Sleep Disturbance T-score

    The primary outcome is PROMIS sleep disturbance, which fulfills the criteria for content validity of a patient-reported outcome with reported relevance, comprehensiveness, ease of use, and treatment responses among people with menopause-related insomnia from diverse geographic locations. Sleep disturbance is one of the most bothersome symptoms of the menopause transition and one of the top reasons health care providers report women seek care. The PROMIS sleep disturbance scale will be used and the possible range of raw score is 8-40. A higher score means higher levels of sleep disturbance. Item responses are combined to yield a T-score with a population mean of 50 and standard deviation of 10.

    Time frame: 6 Months

Secondary outcomes

  1. PROMIS Sleep-related Impairment Score

    Validated questionnaire assessing daytime alertness. The PROMIS sleep-related impairment scale will be used and the possible range of raw score is 8-40. A higher score means higher levels of sleep-related impairment.

    Time frame: 6 months

  2. Sleep latency (average)

    Measurement of time it takes to fall asleep after going to rest. This is measured in time units (minutes, hours) by self-report and Fitbit. This will be analyzed as a 7-day average.

    Time frame: 6 months

  3. Client Satisfaction Measure

    This is measured via the Client Satisfaction Questionnaire. Total scores range from 8 to 32, with the higher number indicating greater satisfaction.

    Time frame: 6 months

  4. Vasomotor Symptoms

    The severity and frequency of vasomotor symptoms assessed via self-report and measured by Likert scale and number of hot flashes per day/night, respectively.

    Time frame: 6 months

  5. Occurrences of events of special interest and/or adverse events

    Occurrence of events of special interest (falls, fall-related injuries, drowsiness, dizziness, headache, nausea, dry mouth, palpitations) will be measured for each arm by self-report or chart review. Occurrence of adverse events will also be assessed by number of participants with treatment-related adverse events as defined by CTCAE v4.0

    Time frame: Throughout the study duration (up to 1 year)

  6. Number of awakenings

    Measure of number of awakenings per night by Fitbit.

    Time frame: 6 months

  7. Sleep duration

    Measured by Fitbit, in hours and minutes.

    Time frame: 6 months

  8. PROMIS Depression Scale

    The PROMIS depression scale will be used and the possible range of raw score is 8-40. A higher score means higher levels of depression symptoms.

    Time frame: 6 months

  9. PROMIS Anxiety Scale

    The PROMIS anxiety scale will be used and the possible range of raw score is 8-40. A higher score means higher levels of anxiety symptoms.

    Time frame: 6 months

  10. PROMIS Cognitive Function Abilities Scale

    The PROMIS cognitive function abilities scale will be used and the possible range of raw score is 4-20. A higher score represents better cognitive function.

    Time frame: 6 months

  11. PROMIS Anger Scale

    The PROMIS anger scale will be used and the possible range of raw score is 5-25. A higher score means higher levels of anger.

    Time frame: 6 months

  12. PROMISE Global Health Score

    The PROMIS global health scale will be used and the possible range of raw score is 8-40. A higher score indicates better physical and mental health.

    Time frame: 6 months

  13. PROMIS Fatigue Score

    The PROMIS fatigue scale will be used and the possible range of raw score is 8-40. A higher score indicates higher levels of fatigue.

    Time frame: 6 months

  14. PROMIS Interest in Sexual Activity Score

    The PROMIS interest in sexual activity scale will be used and the possible range of raw score is 2-10. A higher score indicates greater interest in sexual activity.

    Time frame: 6 months

  15. PROMIS Satisfaction with Sex Life Score

    The PROMIS satisfaction with sex life scale will be used and the possible range of raw score is 4-20. A higher score indicates higher satisfaction with sex life.

    Time frame: 6 months

  16. Menopause-related Quality of Life

    The menopause-related quality of life (MENQOL) scale will be used and the possible range of raw score is 29-232. A higher score indicates higher severity of menopause-related symptoms.

    Time frame: 6 months

  17. Work Productivity and Activity Impairment

    The Work Productivity and Activity Impairment - General Health (WPAI-GH) Questionnaire is a 6-item instrument to measure impairments over the past 7 days in both paid work and unpaid work due to one's health. Higher numbers indicate greater impairment and less productivity. Four main outcomes can be yielded from WPAI and are presented as percentages (0-100%).

    Time frame: 6 months

  18. Insomnia Severity Index

    The Insomnia Severity Index will be used and the possible range of raw score is 0-28. A higher score means more severe symptoms of insomnia.

    Time frame: 6 months

  19. PROMIS Pain Interference

    The PROMIS pain interference scale will be used and the possible range of raw score is 4-20. A higher score means higher levels of pain.

    Time frame: 6 months

07

Study locations

4 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2031, 60 months after the start.

Of 53 non-industry phase 4 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 59. This study's planned 60 months is above that.

Counting every sponsor, half of 58 studies reached it within 28 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Aug 22, 2025
StartActual
Feb 13, 2026
Primary completionEst.
Feb 2031
CompletionEst.
Feb 2031
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07136415
Responsible party
Suzanne M. Bertisch, MD, MPH (Associate Professor of Medicine, Brigham and Women's Hospital) — Principal investigator
First posted
Aug 22, 2025
Start date
Feb 13, 2026
Primary completion
Feb 2031 (estimated)
Completion
Feb 2031 (estimated)
Last update
Jun 8, 2026

Study contacts

Sharon Ng, MS
Contact
shng1@mgh.harvard.edu
617-525-7097
Suzanne Bertisch, MD, MPH
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trazodone · Daridorexant

Start the discussion